These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28363142)

  • 1. Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential.
    Larsson M; Huang WT; Liu DM; Losic D
    Cancer Treat Rev; 2017 Apr; 55():128-135. PubMed ID: 28363142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy].
    Chen WG; Wang SB
    Yao Xue Xue Bao; 2013 Jul; 48(7):1091-8. PubMed ID: 24133974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
    Gandhi NS; Tekade RK; Chougule MB
    J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in research on RNA interference-related drugs for cancer treatment].
    Ren HW; Yang BX
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):801-4. PubMed ID: 23291125
    [No Abstract]   [Full Text] [Related]  

  • 5. Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association.
    Lee E; Oh C; Kim IS; Kwon IC; Kim S
    J Control Release; 2015 Jul; 210():105-14. PubMed ID: 25979325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
    Babu A; Munshi A; Ramesh R
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
    Yadav S; van Vlerken LE; Little SR; Amiji MM
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on RNA interference-mediated gene silencing in cancer therapy.
    Ren YJ; Zhang Y
    Expert Opin Biol Ther; 2014 Nov; 14(11):1581-92. PubMed ID: 25010067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
    Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
    J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA and miRNA for the treatment of cancer.
    Jankovic R; Radulovic S; Brankovic-Magic M
    J BUON; 2009 Sep; 14 Suppl 1():S43-9. PubMed ID: 19785069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanocarrier systems for delivery of siRNA to ovarian cancer tissues.
    Fathabadi EG; Shelling AN; Al-Kassas R
    Expert Opin Drug Deliv; 2012 Jul; 9(7):743-54. PubMed ID: 22657869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Journey of siRNA: Clinical Developments and Targeted Delivery.
    Nikam RR; Gore KR
    Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy.
    Mishra DK; Balekar N; Mishra PK
    Drug Deliv Transl Res; 2017 Apr; 7(2):346-358. PubMed ID: 28050890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in development of siRNA delivery vehicles for cancer therapy.
    Kim HJ; Kim A; Miyata K; Kataoka K
    Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured Hyaluronic Acid-based Materials for the Delivery of siRNA.
    Shah K; Chawla S; Gadeval A; Reddy G; Maheshwari R; Kalia K; Tekade RK
    Curr Pharm Des; 2018; 24(23):2678-2691. PubMed ID: 30084325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the current status of siRNA nanomedicines in the treatment of cancer.
    Resnier P; Montier T; Mathieu V; Benoit JP; Passirani C
    Biomaterials; 2013 Sep; 34(27):6429-43. PubMed ID: 23727262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for tumor-directed delivery of siRNA.
    Chowdhury EH
    Expert Opin Drug Deliv; 2011 Mar; 8(3):389-401. PubMed ID: 21314230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.